New AMA Report Highlights Lack of Competition in PBM Market - MedCity News
Pharmacy Benefit Managers (PBMs) demonstrate a lack of competition and high vertical integration, impacting drug pricing and accessibility for patients.
Most Favored Nation Drug Pricing Will Flop, but What Wouldn't?
Trump's executive order mandates Most Favored Nation pricing to lower U.S. drug prices, aligning them with the lowest prices charged in foreign markets.
Label-Plus Infringement: The Tinderbox Theory of Generic Inducement
Hikma's generic Vascepa, with its "skinny label," poses a challenge for patent protection, potentially undermining the incentives for innovation in the pharmaceutical industry.
Big Pharma Front Groups Muddle Debate Over Drug Prices, Patient Advocates Say
"The group does not include any contact information or details about membership on its website. Seniors 4 Better Care is reportedly a 'shell group' for the American Prosperity Alliance."
Trump wants drug price caps tied to foreign nations. Here's why Biden never did it.
Senate Democrats and the Biden administration abandoned plans to cap drug prices based on payments in other wealthy nations during negotiations to empower Medicare's negotiation capabilities.
Trump's Executive Order to Lower Drug Costs Has No Clear Enforcement Mechanism
Trump's executive order asks drugmakers to voluntarily lower pharmaceutical costs for U.S. consumers, but lacks a definitive mechanism for enforcing these reductions.
Trump Seeks to Lower Drug Prices Through Medicare and Some Imports
Trump's executive order on drug pricing seeks to facilitate drug importation from Canada, though some policies may paradoxically raise costs for Medicare.